Androgen-dependent diseases in dermatology. When and why do I choose spironolactone? Review article
Article Sidebar
Published:
Dec 1, 2024
Keywords:
spironolactone, acne, androgenetic alopecia, seborrhea, hirsutism
Main Article Content
Abstract
Spironolactone has been used in clinical practice for over 60 years, though it remains underappreciated in many respects. Extensive clinical experience with spironolactone, alongside a well-established understanding of its safety profile and potential side effects, allows for its safe, informed use and tailored dosing to match each patient’s needs. This article presents examples of spironolactone’s applications in managing androgen-dependent dermatological conditions.
Article Details
How to Cite
Matusiak, Łukasz. (2024). Androgen-dependent diseases in dermatology. When and why do I choose spironolactone?. Medycyna Faktow (J EBM), 17(3(64), 334-337. https://doi.org/10.24292/01.MF.0324.02
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bolognia JL, Schaffer JV, Cerroni L et al. Dermatologia, wydanie polskie. Medipage, Warszawa 2022.
2. Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review. Eur J Contracept Reprod Health Care. 2017; 3: 172-82.
3. Owczarczyk-Saczonek A, Chojnacka-Purpurowicz J, Placek W. Leki antyandrogenowe. Dermatologia po dyplomie 2022; 4: 23-29.
4. Fauser BCJM, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97: 28-38.
5. Ozdemir S, Ozdemir M, Görkemli H et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010; 89: 199-204.
6. Azziz R, Sanchez L, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004; 89: 453-62.
7. Orfanos CE, Adler YID, Zouboulis CC. The SAHA syndrome. Horm Res. 2000; 54: 251-8.
8. Dreno B, Nguyen JM, Hainaut E et al. Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study. Acta Derm Venereol. 2024; 104: adv 26002.
9. Patibandla S, Heaton J, Kyaw H. Spironolactone. In: StatPearls. StatPearls Publishing, Treasure Island (FL) 2021.
10. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. Uso de la espironolactona en dermatología: acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr (Engl Ed). 2020; 111: 639-49.
11. Reynolds RV, Yeung H, Cheng CE et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024; 90(5): 1006.e1-1006.e30.
12. Szepietowski J, Kapińska-Mrowiecka M, Kaszuba A et al. Trądzik zwyczajny: patogeneza i leczenie. Konsensus Polskiego Towarzystwa Dermatologicznego. Przegl Dermatol. 2012; 99: 649-73.
13. Brough KR, Torgerson RR. Hormonal therapy in female pattern hair loss. Int J Womens Dermatol. 2017; 3: 53-7.
14. Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019; 80: 114-9.
2. Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review. Eur J Contracept Reprod Health Care. 2017; 3: 172-82.
3. Owczarczyk-Saczonek A, Chojnacka-Purpurowicz J, Placek W. Leki antyandrogenowe. Dermatologia po dyplomie 2022; 4: 23-29.
4. Fauser BCJM, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97: 28-38.
5. Ozdemir S, Ozdemir M, Görkemli H et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010; 89: 199-204.
6. Azziz R, Sanchez L, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004; 89: 453-62.
7. Orfanos CE, Adler YID, Zouboulis CC. The SAHA syndrome. Horm Res. 2000; 54: 251-8.
8. Dreno B, Nguyen JM, Hainaut E et al. Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study. Acta Derm Venereol. 2024; 104: adv 26002.
9. Patibandla S, Heaton J, Kyaw H. Spironolactone. In: StatPearls. StatPearls Publishing, Treasure Island (FL) 2021.
10. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. Uso de la espironolactona en dermatología: acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr (Engl Ed). 2020; 111: 639-49.
11. Reynolds RV, Yeung H, Cheng CE et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024; 90(5): 1006.e1-1006.e30.
12. Szepietowski J, Kapińska-Mrowiecka M, Kaszuba A et al. Trądzik zwyczajny: patogeneza i leczenie. Konsensus Polskiego Towarzystwa Dermatologicznego. Przegl Dermatol. 2012; 99: 649-73.
13. Brough KR, Torgerson RR. Hormonal therapy in female pattern hair loss. Int J Womens Dermatol. 2017; 3: 53-7.
14. Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019; 80: 114-9.